Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy

High Alpha Professor Investing Group Follow Summary Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka’s VOYXACT and Vertex’s povetacicept but enjoys a commercial head start and broad label. The probability-weighted model yields a $46 price target (~45% upside), but risks include competition, safety, and cash burn. Looking for a portfolio of ideas like this one? Members of The Total Pharma Tracker get exclusive access to our subscriber-only portfolios. Learn More » PonyWang/E+ via Getty Images I covered Vera Therapeutics, Inc . ( VERA ) in May, when the stock traded at $34.35. I believed Atacicept would receive accelerated approval given the proteinuria reduction, but I just didn’t believe Atacicept had been able to clearly differentiate This article was written by High Alpha Professor 459 Followers Follow Dubai-based investor focused on building a resilient, income-generating portfolio with a long-term growth mindset. My approach is primarily long-only, blending dividend-paying equities, REITs, and other income strategies with selective growth opportunities. I believe in disciplined, fundamentals-driven investing, prioritizing capital preservation while compounding returns over time. Originally from India. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.